<PAGE>
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
SCHEDULE 13D
UNDER THE SECURITIES EXCHANGE ACT OF 1934 (AMENDMENT NO. __)*
CELTRIX PHARMACEUTICALS, INC.
- --------------------------------------------------------------------------------
(NAME OF ISSUER)
COMMON STOCK
- --------------------------------------------------------------------------------
(TITLE OF CLASS OF SECURITIES)
151186103
---------------------------------------------------------------
(CUSIP NUMBER)
ELAN INTERNATIONAL SERVICES, LTD.
C/O BROCK SILVERSTEIN LLC
800 THIRD AVENUE, 21ST FLOOR, NEW YORK, N.Y. 10022 (212) 371-2000
- --------------------------------------------------------------------------------
ATTENTION: DAVID ROBBINS, ESQ.
------------------------------
(NAME, ADDRESS AND TELEPHONE NUMBER OF PERSON AUTHORIZED TO RECEIVE NOTICES
AND COMMUNICATIONS)
APRIL 21, 1999
--------------------------------------------------------------
(DATE OF EVENT WHICH REQUIRES FILING OF THIS STATEMENT)
If the filing person has previously filed a statement on Schedule 13G to report
the acquisition which is the subject of this Schedule 13D, and is filing this
schedule because of ss.ss. 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the
following box.[ ]
Note: Schedules filed in paper format shall include a signed original and five
copies of the schedule, including all exhibits. See ss.240.13d-7(b) for other
parties to whom copies are to be sent.
*The remainder of this cover page shall be filled out for a reporting person's
initial filing on this form with respect to the subject class of securities, and
for any subsequent amendment containing information which would alter
disclosures provided in a prior cover page.
The information required on the remainder of this cover page shall not be deemed
to be "filed" for the purpose of Section 18 of the Securities Exchange Act of
1934 ("Act") or otherwise subject to the liabilities of that section of the Act
but shall be subject to all other provisions of the Act (however, see the
Notes).
Page 1 of 6
<PAGE>
SCHEDULE 13D
- -------------------------------------------------------------------------------
CUSIP NO. 151186103 PAGE 2 OF 7 PAGES
- -------------------------------------------------------------------------------
1 NAMES OF REPORTING PERSONS I.R.S.
IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)
Elan International Services, Ltd.
- -------------------------------------------------------------------------------
2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) [ ]
(SEE INSTRUCTIONS) (b) [ ]
- -------------------------------------------------------------------------------
3 SEC USE ONLY
- -------------------------------------------------------------------------------
4 SOURCE OF FUNDS (SEE INSTRUCTIONS)
WC
- -------------------------------------------------------------------------------
5 CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED
PURSUANT TO ITEMS 2(D) OR 2(E) [ ]
- -------------------------------------------------------------------------------
6 CITIZENSHIP OR PLACE OF ORGANIZATION
Bermuda
- -------------------------------------------------------------------------------
7 SOLE VOTING POWER
NUMBER OF 5,501,771 shares (assumes conversion of 8,010 shares of
SHARES Series A Preferred Stock into 3,993,020 shares of Common
BENEFICIALLY Stock as of July 26, 1999)
OWNED BY -------------------------------------------------------------------
EACH 8 SHARED VOTING POWER
REPORTING - 0 -
PERSON -------------------------------------------------------------------
WITH 9 SOLE DISPOSITIVE POWER
5,501,771 shares
- -------------------------------------------------------------------------------
10 SHARED DISPOSITIVE POWER
- 0 -
- -------------------------------------------------------------------------------
11 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
5,501,771 shares
- -------------------------------------------------------------------------------
12 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES
CERTAIN SHARES (SEE INSTRUCTIONS)
- -------------------------------------------------------------------------------
13 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
18.0% (based on 30,562,824 shares of the Issuer outstanding as of June 1,
1999, as reported on the Issuer's Annual Report on Form 10-K for the year
ended March 31, 1999; assumes conversion of 8,010 shares of Series A
Preferred Stock but not of any other common stock equivalents)
- -------------------------------------------------------------------------------
14 TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
CO
- -------------------------------------------------------------------------------
<PAGE>
ITEM 1. SECURITY AND ISSUER.
Common Stock, par value $.01 per share (the "Common Stock")
Celtrix Pharmaceuticals, Inc.
2033 Gateway Place, Suite 600
San Jose, CA 95110
ITEM 2. IDENTITY AND BACKGROUND.
This Form 13-D is filed by Elan International Services, Ltd., a
Bermuda corporation ("EIS"), 102 St. James Court, Flatts, Smiths Parish, FL 04,
Bermuda. EIS is a wholly-owned subsidiary of Elan Corporation, plc, Lincoln
House, Lincoln Place, Dublin 2, Ireland, an Irish public limited company
("Elan"). During the last five years, none of the persons named above in this
Item 2: (i) has been convicted in a criminal proceeding (excluding traffic
violations or similar misdemeanors); or (ii) was a party to a civil proceeding
of a judicial or administrative body of competent jurisdiction, as a result of
which proceeding it was or is subject to a judgment, decree or final order
enjoining future violations of, or prohibiting or mandating activities subject
to, United States federal or state securities laws, or finding any violation
with respect to such laws.
ITEM 3. SOURCE AND AMOUNT OF FUNDS OR OTHER CONSIDERATION.
On April 21, 1999, pursuant to the terms of a letter agreement dated
March 31, 1999, by and among Elan and EIS on the one hand, and Celtrix
Pharmaceuticals, Inc., a Delaware corporation (the "Issuer"), on the other hand,
EIS acquired (a) 1,508,751 shares (the "Initial Shares") of Common Stock of the
Issuer, and (b) 8,010 shares of Series A Convertible Preferred Stock (the
"Series A Preferred," and together with the Initial Shares, the "Securities") of
the Issuer for aggregate consideration of $10,510,000. The Series A Preferred
pays for 36 months dividends of 5% of its issue price through the issuance of
additional shares of Series A Preferred. Additionally, EIS has the right to
acquire up to 4,800 shares of the Series B Convertible Preferred Stock (the
"Series B Preferred") of the Issuer. The consideration for the Securities was
provided by EIS's general corporate funds. As of July 26, 1999, (i) the Series A
Preferred, together with dividends thereon, was convertible into 3,993,020
shares of Common Stock and (ii) no shares of the Series B Preferred have been
issued to EIS..
ITEM 4. PURPOSE OF TRANSACTION.
EIS acquired the Securities for investment purposes.
Except as set forth above, neither EIS nor Elan has a plan or proposal
which relates to or would result in:
(a) The acquisition by any person of additional securities of the
Issuer, or the disposition of securities of the Issuer;
(b) An extraordinary corporate transaction such as a merger,
reorganization or liquidation involving the Issuer or any of its subsidiaries;
(c) A sale or transfer of a material amount of assets of the Issuer or
any of its subsidiaries;
(d) Any change in the present Board of Directors or management of the
Issuer, including any plans or proposals to change the number of or term of
Directors or to fill any existing vacancies on the Board;
(e) Any material change in the present capitalization or dividend
policy of the Issuer;
(f) Any other material change in the Issuer's business or corporate
structure;
Page 3 of 6
<PAGE>
(g) Changes in the Issuer's charter, by-laws, or instruments
corresponding thereto or other actions which may impede the acquisition of
control of the Issuer by any person;
(h) Causing the Common Stock to cease to be authorized to be traded on
the Nasdaq National Market System.
(i) To have the Common Stock terminated from registration under the
Securities Act of 1933; or
(j) Any action similar to any of those enumerated above.
ITEM 5. INTEREST IN THE SECURITIES OF THE ISSUER.
(a) 5,501,771 shares of Common Stock, representing 18.0% (based upon
26,569,804 shares of the Issuer outstanding as of June 1, 1999, as reported in
the Issuer's Annual Report on Form 10-K for the year ended March 31, 1999 and
3,993,020 shares of Common Stock reserved for issuance on conversion of the
Series A Preferred).
(b) sole power to vote: 5,501,771shares
shared power to vote: -0-
sole power to dispose: 5,501,771 shares
shared power to dispose: -0-
(c) None.
(d) None.
(e) Not Applicable.
ITEM 6. CONTRACTS, ARRANGEMENTS, UNDERSTANDINGS OR RELATIONSHIPS WITH RESPECT
TO SECURITIES OF THE ISSUER.
Not Applicable.
ITEM 7. MATERIAL TO BE FILED AS EXHIBITS.
1. Securities Purchase Agreement, dated April 21, 1999
Page 4 of 6
<PAGE>
SIGNATURES
After reasonable inquiry and to the best of my knowledge and belief,
the undersigned certifies that the information set forth in this statement is
true, complete and correct.
Date: August 30, 1999
Elan International Services, Ltd.
By: /s/ Kevin Insley
--------------------------------
Kevin Insley
President
Page 5 of 6
<PAGE>
EXHIBIT INDEX
1. Securities Purchase Agreement, dated April 21, 1999
Page 6 of 6
<PAGE>
EXECUTION COPY
--------------
SECURITIES PURCHASE AGREEMENT
SECURITIES PURCHASE AGREEMENT (the "Agreement"), dated as of April 21,
1999, between CELTRIX PHARMACEUTICALS INC., a Delaware corporation (the
"Company"), and ELAN INTERNATIONAL SERVICES, LTD., a Bermuda exempted company
("EIS").
R E C I T A L S:
A. The Company desires to issue and sell to EIS, and EIS desires to
purchase from the Company, 1,508,751 shares of Common Stock of the Company at a
price of U.S$1.657 per share (the "Common Stock"), which shall be issued to EIS
pursuant to this Agreement. The Company desires to issue and sell to EIS, and
EIS desires to purchase from the Company, 8010 shares, consisting of all of the
issued and outstanding shares, of a newly-created series of convertible/
exchangeable preferred stock, captioned Series A Preferred Stock (the
"Series A Preferred Stock"), which shall be issued to EIS pursuant to this
Agreement. The Company also desires to issue and sell to EIS, and EIS desires to
purchase from the Company from time to time, as provided herein, up to 4,800
shares of the Series B Convertible Preferred Stock at a price of U.S.$1,000.00
per share (the "Series B Preferred Stock"; together with the Series A Preferred
Stock, the "Preferred Stock" or the "Securities") which Securities shall be
issued to EIS pursuant to this Agreement, in accordance with its terms and
subject to the conditions contained herein. The rights, preferences and
privileges of the Preferred Stock are as set forth in the Amended and Restated
Certificate of Incorporation of the Company (the "Amended and Restated
Certificate of Incorporation") in the form attached hereto as Exhibit A.
B. The Company and EIS have previously caused to be formed Celtrix
Newco, Ltd., a Bermuda exempted company ("Newco"), and pursuant to the terms of
a Subscription, Joint Development and Operating Agreement dated as of the date
hereof (as amended at any time, the "JDOA"), simultaneously with the
transactions contemplated by this Agreement: (i) the Company shall acquire 9,612
ordinary shares of Newco, par value U.S.$1.00 per share (the "Newco Common
Stock"), and (ii) EIS shall acquire 2,388 shares of Newco Common Stock; and, as
of the date hereof, Newco has entered into license agreements with (i) ELAN
CORPORATION, PLC, an Irish public limited company and parent corporation of EIS
("Elan"; such agreement, as amended at any time, the "Elan License Agreement"),
and (ii) the Company (as amended at any time, the "Celtrix License Agreement";
together with the Elan License Agreement, the "License Agreements").
C. The Company and EIS are executing and delivering on the date
hereof a Registration Rights Agreement, in the form attached hereto as Exhibit B
(as amended at any time, the "Celtrix Registration Rights Agreement"), in
respect of the Common Stock underlying the Series A Preferred Stock and the
Series B Preferred Stock, and any other Common Stock of the Company that is
issued to EIS or any of its affiliates or permitted transferees upon any stock
split, stock dividend, recapitalization or similar event affecting the Series A
Preferred Stock or the Series B Preferred Stock or the Common Stock issued or
issuable on conversion thereof. The
<PAGE>
Company, EIS and Newco are executing and delivering on the date hereof a
Registration Rights Agreement in the form attached hereto as Exhibit C (as
amended at any time, the "Newco Registration Rights Agreement"). Additionally,
the Company and EIS are executing and delivering on the date hereof a Funding
Agreement in the form attached hereto as Exhibit D (the "Funding Agreement";
together with this Agreement, the Amended and Restated Certificate of
Incorporation, the JDOA, the Newco Registration Rights Agreement, the Celtrix
Registration Rights Agreement, the License Agreements and each other document or
instrument executed and delivered in connection with the transactions
contemplated hereby and by the JDOA, the "Transaction Documents"), pursuant to
which each of the Company and EIS have agreed to provide certain funds to Newco.
A G R E E M E N T:
The parties agree as follows:
SECTION 1. Closing. (a) Time and Place. The closing of the
transactions contemplated hereby (the "Closing") shall occur on the date hereof
(the "Closing Date"), at the offices of counsel to EIS in New York City.
(b) Issuance of Securities. At the Closing, the Company shall issue
and sell to EIS, and EIS shall purchase from the Company 1,508,751 shares of
Common Stock and 8,010 shares of Series A Preferred Stock. In addition, the
Company shall issue shares of Series B Preferred Stock as set forth in Section
1(g) hereof.
(c) Purchase Price. The purchase price (the "Purchase Price") shall be
the sum of (i) $8.01 million for the Series A Preferred Stock and (ii) $2.5
million for the Common Stock.
(d) Delivery. At the Closing:
(i) EIS shall pay the Purchase Price, by wire transfer to an
account designated by the Company and the parties hereto shall execute and
deliver to each other, as applicable: (A) certificates for the Common Stock
and the Series A Preferred Stock; (B) the Celtrix Registration Rights
Agreement; (C) the Newco Registration Rights Agreement; (D) the JDOA;
(E) the Amended and Restated Certificate of Incorporation, as theretofore
filed with the Secretary of State of the State of Delaware; (F) the License
Agreements; (G) the Funding Agreement; (H) certificates as to the incumbency
of the officers of the Company executing this Agreement; and (I) each of the
other documents or instruments to be executed in connection herewith.
(ii) The Company shall cause to be delivered to EIS an opinion of
counsel in form attached hereto as Exhibit E.
(e) Exemption from Registration. The Securities and any underlying
shares of Common Stock or Preferred Stock will be issued under an exemption or
exemptions from
2
<PAGE>
registration under the Securities Act of 1933, as amended (the "Securities
Act"); accordingly, the certificates evidencing the Series A Preferred Stock and
Series B Preferred Stock, and any shares of Preferred Stock or Common Stock or
other securities issuable upon the exercise, conversion or exchange of any of
the Securities shall, upon issuance, contain a legend, substantially in the form
as follows:
THE SECURITIES REPRESENTED HEREBY HAVE NOT BEEN REGISTERED UNDER THE
SECURITIES ACT OF 1933, AS AMENDED OR ANY SECURITIES LAWS OF A STATE OR
OTHER JURISDICTION AND MAY NOT UNDER ANY CIRCUMSTANCES BE SOLD, TRANSFERRED,
OR OTHERWISE DISPOSED OF (OTHER THAN TO AN AFFILIATE OF THE ORIGINAL HOLDER)
EXCEPT PURSUANT TO (I) AN EFFECTIVE REGISTRATION STATEMENT UNDER THE
SECURITIES ACT AND ANY APPLICABLE STATE SECURITIES OR BLUE SKY LAWS, OR
(II) TO THE EXTENT APPLICABLE, RULE 144 UNDER THE SECURITIES ACT (OR ANY
SIMILAR RULE UNDER THE SECURITIES ACT RELATING TO THE DISPOSITION OF
SECURITIES) TOGETHER WITH AN OPINION OF COUNSEL REASONABLY SATISFACTORY TO
THE CORPORATION THAT REGISTRATION IS NOT REQUIRED UNDER SUCH ACT OR
APPLICABLE STATE SECURITIES LAWS.
(f) Registration Rights Agreement. On the date hereof, each of the
Company and EIS is executing and delivering the Celtrix Registration Rights
Agreement, in respect of the Common Stock underlying the Series A Preferred
Stock and the Series B Preferred Stock, and any other Common Stock of the
Company that is issued to EIS or any of its affiliates or permitted transferees
upon any stock split, stock dividend, recapitalization or similar event
affecting the Series A Preferred Stock or the Series B Preferred Stock or the
Common Stock issued or issuable on conversion thereof.
(g) Series B Preferred Stock. The Company shall issue and sell to EIS,
and EIS shall purchase from the Company, from time to time, shares of Series B
Preferred Stock, up to a maximum of 4,800 shares, in accordance with the
following terms and conditions:
(i) Each purchase and sale shall be made at such time that Newco's
board of directors shall have determined that funding is required under the
JDOA, in accordance with the terms thereof, and Newco shall have provided
written notice thereof to EIS and to the Company; the proceeds of the
Series B Preferred Stock shall be used solely to satisfy the Company's
obligation to provide such funding;
(ii) The price per share shall be U.S.$1,000.00, and shares shall
be issued only in 250-share increments;
3
<PAGE>
(iii) A condition to each such purchase shall be (A) that it shall
occur prior to the date that is 24 months after the date hereof and
(B) that there is no material breach or default by the Company hereunder or
under the JDOA or the Funding Agreement and the representations herein
shall be true and correct in all material respects as of the date made and
as of the proposed funding date (updated as to SEC Filings and similar
matters); and
(iv) Purchases and sales of shares of Series B Preferred Stock
shall be made upon at least 10 days' written notice from the Company to EIS,
which notices shall set forth a closing date; on each such closing date,
(x) EIS shall fund the amount required to purchase such shares, as provided
herein, and (y) the Company shall cause to be delivered to EIS a certificate
or certificates in respect thereof and a confirmation that the conditions
described in clause (iii) above have been satisfied.
SECTION 2. Representations and Warranties of the Company. The Company
hereby represents and warrants to EIS, as of the Closing (and any later date of
funding of any Series B Preferred Stock, as provided herein), and except as set
forth on the applicable schedules hereof, as follows:
(a) Organization. The Company is duly organized, validly existing and
in good standing under the laws of the State of Delaware and has all requisite
corporate power and authority to own and lease its properties, to carry on its
business as presently conducted and as proposed to be conducted and to
consummate the transactions contemplated hereby. The Company is qualified and in
good standing to do business in the State of California, which constitutes all
the jurisdictions in which the nature of the business conducted or the property
owned by it requires such qualification, except where the failure to so qualify
would not have a material adverse effect on the business, prospects, properties
or condition (financial or otherwise) of the Company (a "Material Adverse
Effect").
(b) Capitalization. (i) The authorized capital stock of the Company as
of the date hereof consisted of 60 million shares of Common Stock, of which
25,061,053 were issued and outstanding, and 10 million shares of Preferred
Stock, of which (A) 10,000 are designated as Series A Preferred Stock, none of
which were issued or outstanding, and (B) 9,000 are designated as Series B
Preferred Stock, none of which shares were issued and outstanding.
(ii) Except as listed in Schedule 2(b) and in the Company's
filings with the Securities and Exchange Commission on or prior to the date
hereof (the "SEC Filings"), as of the Closing Date there are no options,
warrants or other rights outstanding to purchase, subscribe for or otherwise
acquire, or any securities convertible into, any of the Company's authorized
capital stock. Other than as set forth in this Agreement and as described in
Schedule 2(b), there are no agreements, arrangements or understandings
concerning the voting, acquisition or disposition of any of the Company's
outstanding securities to which the Company is a party or of which it is
otherwise aware, and, other than as set forth in Schedule 2(b) or in the
Registration Rights Agreement, there are no agreements to register any of the
Company's outstanding securities under the U.S. Federal securities laws.
4
<PAGE>
(iii) All of the outstanding shares of capital stock of the
Company have been issued in accordance with applicable state and federal laws
and regulations governing the sale and purchase of securities, all of such
shares of have duly and validly issued and are fully paid and non-assessable,
and none of such shares carries preemptive or similar rights.
(c) Authorization of Transaction Documents. The Company has full
corporate power and authority to execute and deliver this Agreement and each of
the other Transaction Documents, and to perform its obligations hereunder and
thereunder. The execution, delivery and performance by the Company of the
Transaction Documents have been duly authorized by all requisite corporate
actions by the Company; and the Transaction Documents, including the issuance
and sale of the Securities, when executed and delivered by the Company, will be
the valid and binding obligations of the Company, enforceable against the
Company in accordance with their respective terms.
(d) No Violation. Subject to compliance with applicable requirements
of the Securities Act or any other applicable securities laws of a state or
other jurisdiction, the execution, delivery and performance by the Company of
the Transaction Documents, including the issuance and sale of the Securities,
and compliance with the provisions thereof, will not (i) violate any provision
of applicable law, statute, rule or regulation applicable to the Company or any
ruling, writ, injunction, order, judgment or decree of any court, arbitrator,
administrative agency or other governmental body applicable to the Company or
any of their respective properties or assets or (ii) conflict with or result in
a breach of any of the terms, conditions or provisions of, or constitute (with
notice or lapse of time or both) a default (or give rise to any right of
termination, cancellation or acceleration) under, or result in the creation of,
any Encumbrance (as defined below) upon any of the properties or assets of the
Company under its Certificate of Incorporation, as amended, or bylaws, or any
contract to which the Company is a party, except where such violation, conflict
or breach would not, individually or in the aggregate, have a Material Adverse
Effect. As used herein, "Encumbrance" shall mean any liens, charges,
encumbrances, equities, claims, options, proxies, pledges, security interests,
or other similar rights of any nature that would, individually or in the
aggregate, have a Material Adverse Effect.
(e) Approvals. No material permit, authorization, consent or approval
of or by, or any notification of or filing with, any person or entity
(governmental or otherwise) is required in connection with the execution,
delivery or performance of the Transaction Documents, including the issuance and
sale of the Securities, by the Company, other than any applicable notice and
filing requirements under state blue sky laws, the Securities Act and the
Hart-Scott-Rodino Antitrust Improvements Act (upon conversion and/or exchange of
the Series A Preferred Stock and the Series B Preferred Stock).
(f) Filings, Taxes and Financial Statements. (i) The Company has filed
its annual report on Form 10-K for the fiscal year ended March 31, 1998 (the
"Annual Report"), its related proxy materials and the quarterly reports on Form
10-Q for the quarters ended June 30, 1998, September 30, 1998 and December 31,
1998 (the "Quarterly Reports") with the Securities and Exchange Commission and
any other required person or entity (governmental or otherwise) in a
5
<PAGE>
timely manner and as otherwise required by applicable laws and regulations,
including the federal securities acts. The audited financial statements of the
Company for the fiscal year ended March 31, 1998 included in the Annual Report
(the "Audited Financial Statements"), and the Company's unaudited balance sheet
for the period ending December 31, 1998, together with the accompanying
statements of operations and cash flows including the notes thereto (the
"December Financial Statements"; collectively, with the Audited Financial
Statements, the "Financial Statements") are accurate and complete in all
material respects and fairly present the financial condition of the Company as
at the dates thereof and have been prepared in accordance with generally
accepted accounting principles applied on a consistent basis throughout the
periods indicated (except as may be otherwise indicated in such financial
statements or the notes thereto), subject, in the case of the December Financial
Statements, to normal year-end audit adjustments (which shall not be material in
the aggregate) and the absence of footnote disclosures. The Company has not
incurred and is not liable for any material obligations or liabilities except as
set forth in the December 31, 1998 balance sheet or as otherwise disclosed in
writing to EIS.
(ii) The Company has filed in a timely manner all material federal,
state, local and foreign tax returns, reports and filings (collectively,
"Returns"), including income, franchise, property and other taxes, and has paid
or accrued the appropriate amounts reflected on such Returns. None of the
Returns have been audited or challenged, nor has the Company received any notice
of challenge nor have any of the amounts or other data included in the Returns
been challenged or reviewed by any governmental authority.
(iii) As of the Closing Date, the Company does not maintain, sponsor,
is not required to make contributions to or otherwise have any liability with
respect to any pension, profit sharing, thrift or other retirement plan,
employee stock ownership plan, deferred compensation, stock ownership, stock
purchase, performance share, bonus or other incentive plan.
(g) Properties and Assets; Etc. (i) The Company does not own any
interest in real property, and (ii) the Company owns or has the right to use
pursuant to license, sub-license, agreement or permission all Intellectual
Property which, to the Company's knowledge, is necessary for the operation of
its business as presently conducted, including patents, patent applications,
continuations, continuations-in-part, extensions, trademarks and trademark
applications, know-how and other intellectual property, as reflected in the
Financial Statements, subject in each case, to no Encumbrances required to be
disclosed in the Financial Statements except as set forth therein. Except as set
forth on Schedule 2(g), (A) all of the Company's patents, trademarks, service
marks, trade names, and copyrights which are owned by the Company are owned free
and clear of all liens, claims and encumbrances and are valid and duly issued or
existing; none of the Company's rights in or use of such patents, trademarks,
service marks, trade names or copyrights has been or, to the Company's
knowledge, is currently being threatened to be, challenged; to the Company's
knowledge, no current or currently planned product based upon the Company's
intellectual property would infringe any patent, trademark, service mark, trade
name or copyright of any other person or entity issued or pending on the Closing
Date if the Company were to distribute, sell or manufacture such products; and
the
6
<PAGE>
Company is not aware, after due inquiry, of any actual or threatened claim by
any person or entity alleging any infringement by the Company of a patent,
trademark, service mark, trade name or copyright possessed by such Person; (B)
all of such patents, trademark registrations, service mark registrations, trade
name registrations and copyrights and copyright registrations, whether foreign
or domestic, have been duly issued and have not been canceled, abandoned, or
otherwise terminated; and (C) all of the Company's patent applications,
trademark applications, service mark applications, trade name applications and
copyright applications have been duly filed.
(ii) Each of the contracts listed as an exhibit to the Company's
Annual Report (each, a "Contract") is a legal and valid agreement binding upon
each of the parties thereto and is in full force and effect and, to the best
knowledge of the Company, there is no breach or default by any party thereunder.
Such Contracts constitute all material agreements, arrangements or
understandings required to be included in such Annual Report under Securities
and Exchange Commission regulations promulgated in connection therewith.
(iii) The Company has and maintains adequate and sufficient insurance,
including liability, casualty and products liability insurance, covering risks
associated with its business, properties and assets, including insurance that is
customary for companies similarly situated.
(iv) To its best knowledge, the Company, its business and properties
and assets are in compliance, in all material respects, with all applicable laws
and regulations, including without limitation, those relating to (a) health,
safety and employee relations, (ii) environmental matters, including the
discharge of any hazardous or potentially hazardous materials into the
environment, and (iii) the development, commercialization and sale of
pharmaceutical and biotechnology products, including all applicable regulations
of the U.S. Food and Drug Administration and comparable foreign regulatory
authorities.
(h) Absence of Changes. From December 31, 1998 until the Closing,
there has not been (a) any change having a Material Adverse Effect in the
business, properties, condition (financial or otherwise), operations or
prospects of the Company; (b) any damage, destruction or loss, whether or not
covered by insurance having a Material Adverse Effect; (c) any declaration,
setting aside or payment of any dividend or other distribution or payment
(whether in cash, stock or property) in respect of the capital stock of the
Company, or any redemption or other acquisition of such stock by the Company
except for the repurchase of such stock pursuant to the termination of employees
or consultants; (d) any disposal or lapse of any trade secret, invention,
patent, patent application or continuation (in whole or in part) trademark,
trademark registration, service mark, service mark registration, copyright,
copyright registration, or any application therefor or filing in respect thereof
(collectively, and together with any and all know-how, trade secrets and
proprietary business of technology information, the "Intellectual Property");
(e) loss of the services of any of the key officers or key employees of the
Company; (f) any incurrence of or entry into any liability, mortgage,
Encumbrance, commitment or transaction, including without limitation, any
borrowing (or assumption or guarantee thereof) or guarantee of a third party's
obligations; or (g) any material change by the Company in accounting methods or
principles or (h) any change in the assets, liabilities, condition (financial or
otherwise), results of
7
<PAGE>
operations or prospects of the Company, except changes in the ordinary course of
business that, individually or in the aggregate, have not had or would not
reasonably be expected to have a Material Adverse Effect.
(i) No Liabilities. Except as set forth in the SEC Filings or Schedule
2(i), the Company has not incurred or suffered any individual liability or
obligation, matured or unmatured, contingent or otherwise, that exceeds
U.S.$100,000, other than in the ordinary course of business and that has not,
individually or in the aggregate with any other such liabilities or obligations,
had a Material Adverse Effect.
(j) Legal Proceedings, etc. There is no legal, administrative,
arbitration or other action or proceeding or governmental investigation pending
or to the Company's knowledge threatened against the Company, or any director,
officer or employee of the Company. The Company is not in violation of or
default under, any material laws, judgments, injunctions, orders or decrees of
any court, governmental department, commission, agency, instrumentality or
arbitrator known by the Company, or which reasonably should be expected to be
known by the Company, to be applicable to it or its business that, if determined
adversely to the Company, (i) may have a Material Adverse Effect on the Company
or any of its properties or assets or (ii) disturb or challenge the validity or
performance of this Agreement or the other Transaction Documents to which the
Company is a party.
(k) Disclosure. The Company's SEC Filings and the representations and
warranties set forth herein and in the other Transaction Documents, when viewed
collectively, do not contain any untrue statement of a material fact or omit to
state any material fact necessary to make the statements contained herein and
therein not misleading.
(l) Brokers or Finders. The Company has not retained any investment
banker, and is not liable for any fee or payment to any such person, broker or
finder in connection with the transactions contemplated by the Transaction
Documents.
(m) Year 2000. The Company, uses, licenses, leases or owns, directly
or indirectly, by or on behalf of or for the account of the Company, whether in
development, in production form or otherwise, electronic data processing
systems, information systems, computer software programs, program
specifications, charts, procedures, input data, routines, data bases, report
layouts, formats, record file layouts, diagrams, functional specifications,
narrative descriptions, flow charts and other related material (the "Software")
which to the Company's best knowledge, correctly recognizes and processes
four-digit year-dates, including the correct recognition of February 29th during
the leap year, and will continue to function properly with regard to dates
before, during and after transition to the year 2000.
SECTION 3. Representation and Warranties of EIS. EIS hereby represents
and warrants to the Company, as of the date hereof, as follows:
(a) Organization. EIS is an exempted company duly organized and
validly existing and in good standing under the laws of Bermuda and has all
requisite corporate power
8
<PAGE>
and authority to own and lease its properties, to carry on its business as
presently conducted and as proposed to be conducted and to consummate the
transactions contemplated hereby. EIS is qualified and in good standing to do
business in each jurisdiction in which the nature of the business conducted or
the property owned by it requires such qualification, except where the failure
to so qualify would not reasonably be expected to have a Material Adverse Effect
on EIS.
(b) Authorization of Agreement. EIS has full legal right, power and
authority to execute and deliver this Agreement and each other Transaction
Document to which it is a party, and to purchase and accept the Preferred Stock,
and perform its obligations hereunder, which have been duly authorized by all
requisite corporate action. The execution, delivery, and performance by EIS of
this Agreement and each other Transaction Document to which it is a party, have
been duly authorized by all requisite actions by EIS; and this Agreement and
each other Transaction Document to which it is a party, including the purchase
of Securities have been duly executed and delivered by and are the valid and
binding obligations of EIS, enforceable against it in accordance with its terms.
(c) No Conflicts. The execution, delivery and performance by EIS of
this Agreement and each Transaction Document, the purchase and acceptance of the
Preferred Stock and compliance with provisions hereof and thereof by EIS, will
not (i) violate any provisions of applicable law, statute, rule or regulation
applicable to EIS or any ruling, written, injunction, order, judgment or decree
of any court, arbitration, administrative agency of other governmental body
applicable to EIS of any of its properties or assets or (ii) conflict with or
result in any breach of any of the terms, conditions or provisions of, or
constitute (with notice or lapse of time to both) a default (or give rise to any
right of termination, cancellation or acceleration) under, or result in the
creation of any Encumbrance upon any of the properties or assets of EIS under
the Memorandum and Articles of Association of EIS or any material contract to
which EIS is party, except where such violation conflict or breach would not,
individually or in the aggregate, have a Material Adverse Effect on EIS.
(d) Approvals. No permit, authorization, consents or approval of or
by, or any notification of or filing with, any person or entity (governmental or
otherwise) is required in connection with the execution, delivery or performance
of this Agreement or the Transaction Documents by EIS.
(e) Investment Representations. (i) EIS is sophisticated in
transactions of this type and capable of evaluating the merits and risks of the
transactions described herein and in the other Transaction Documents, and has
the capacity to protect its own interests. EIS has not been formed solely for
the purpose of entering into the transactions described herein and therein and
is acquiring the Securities for investment for its own account, not as a nominee
or agent, and not with the view to, or for resale, distribution or
fractionalization thereof, in whole or in part, and no other person has a direct
or indirect interest, beneficial or otherwise in the Securities; provided, that
EIS shall be permitted to convert or exchange such Securities.
(ii) EIS has not and does not intend to enter into any contract,
undertaking, agreement or arrangement with any person or entity to sell,
transfer or pledge the Securities.
9
<PAGE>
(iii) EIS acknowledges its understanding that the private placement
and sale of the Securities is exempt from registration under the Securities Act
and Section 4(2) of the Securities Act and the provisions of Regulation D
promulgated thereunder ("Regulation D"). In furtherance thereof, EIS represents
and warrants that it is an "accredited investor" as that term is defined in
Regulation D, has the financial ability to bear the economic risk of its
investment, has adequate means for providing for its current needs and personal
contingencies and has no need for liquidity with respect to its investment in
the Company.
(iv) EIS agrees that it shall not sell or otherwise transfer any of
the Securities without registration under the Securities Act or pursuant to an
opinion of counsel reasonably satisfactory to the Company's counsel that an
exemption from registration is available, and fully understands and agrees that
it must bear the total economic risk of its purchase for an indefinite period of
time because, among other reasons, none of the Securities have been registered
under the Securities Act or under the securities laws of any applicable state or
other jurisdiction and, therefore, cannot be resold, pledged, assigned or
otherwise disposed of unless subsequently registered under the Securities Act
and under the applicable securities laws of such states or jurisdictions or an
exemption from such registration is available. EIS understands that the Company
is under no obligation to register the Securities on its behalf with the
exception of certain "demand" and "piggyback" registration rights, with respect
to certain of the Securities, as provided in the Celtrix Registration Rights
Agreement. EIS understands the lack of liquidity and restrictions on transfer of
the Securities and that this investment is suitable only for a person or entity
of adequate financial means that has no need for liquidity of this investment
and that can afford a total loss of its investment.
(f) Brokers or Finders. EIS has not retained any investment banker,
broker, finder or person or entity acting in a similar capacity, and is not
liable for any fee or payment to any such person, in connection with the
transactions contemplated by the Transaction Documents.
(g) Litigation. There is no litigation or governmental,
administrative, arbitration or other action or proceeding or governmental
investigation pending or to EIS's knowledge threatened against EIS or any
director or officer or employee thereof that, if determined adversely to EIS,
(i) may have a Material Adverse Effect on EIS or any of its properties or assets
or (ii) disturb or challenge the validity or performance of this Agreement or
the other Transaction Documents to which EIS is a party.
SECTION 4. Covenants of the Parties. (a) Operating Covenants. From and
after the Closing Date and until the earlier to occur of the exercise or
expiration of the Exchange Right (as such term is defined in Section 5 hereof)
the Company shall not without the prior written consent of EIS encumber, pledge
or otherwise affect, in any respect, its ownership of any shares of Newco owned
by the Company or transferable to EIS upon exercise by EIS of the Exchange Right
or its ability to permit EIS to exercise the Exchange Right, in full, as
provided herein.
(b) Fully-diluted Stock Ownership. Notwithstanding any other provision
of this Agreement, in the event that EIS shall have determined that at any time
it (together with its
10
<PAGE>
affiliates or subsidiaries, if applicable) holds or has the right to receive
Common Stock (or securities or rights, options or warrants exercisable,
exchangeable or convertible for or into Common Stock) representing in the
aggregate in excess of 19.9% of the Company's outstanding Common Stock on a
fully diluted basis (assuming the exercise, exchange or conversion of such
securities beneficially owned by EIS or its affiliates, but not the exercise,
exchange or conversion of any other similar securities), EIS shall have the
right, in its sole discretion, rather than acquiring such securities from the
Company, to exchange such number of securities, as are necessary to bring its
holdings to below the excess of 19.9% of the voting securities of the Company,
for non-voting, convertible liquidation preferred stock of the Company (which
shall be reasonably satisfactory to each of the Company and EIS), which equity
securities shall be entitled to all of the other rights and benefits of the
Common Stock. In the event that EIS shall undertake to exercise such right, EIS
shall retain the additional right to exchange such new class of equity security
for Common Stock, in its discretion on terms that are mutually agreeable to the
Company and EIS.
Each of the Company and EIS shall use commercially reasonable effort
to effect such transactions and any required subsequent conversions or
adjustments to such securities, on a quarterly basis, within 10 business days of
the end of EIS' fiscal quarter.
(c) Use of Proceeds. The Company shall use the proceeds of (i) the
issuance and sale of the Series A Preferred Stock solely to meet its initial
capitalization and its initial funding obligations to Newco as described in the
License Agreements and the JDOA, and (ii) the issuance and sale of the Series B
Preferred Stock solely to meet its developmental funding obligations as
described in the JDOA and the Funding Agreement.
(d) Confidentiality; Non-disclosure. (i) Subject to clauses (ii),
(iii) and (iv) below, from and after the date hereof, and except as may be
required by applicable law or judicial or administrative process, neither the
Company nor EIS (nor their respective affiliates) shall disclose to any person
or entity this Agreement or the other Transaction Documents or the contents
thereof or the parties thereto, except that such parties may make such
disclosure to their directors, officers, employees and advisors, so long as they
shall have advised such persons of the obligation of confidentiality herein and
for whose breach or default the disclosing shall be responsible; it being
understood that the Company will file this Agreement with the Securities and
Exchange Commission pursuant to applicable law. The non-disclosing party shall
be entitled to seek injunctive or other equitable relief in respect of any
breach or threatened breach of the foregoing covenants without the requirement
of posting a bond or other collateral.
(ii) Prior to issuing any press release or public disclosure in
respect of this Agreement or the transactions contemplated hereby, the party
proposing such issuance shall obtain the consent of the other party to the
contents thereof, which consent shall not be unreasonably withheld or delayed;
it being understood that if such second party shall not have responded to such
consent request within one business day, such consent shall be deemed given.
(iii) This Section 4(d) shall not be construed to prohibit
disclosure by the receiving party of any information which has not been
previously determined to be confidential
11
<PAGE>
by the disclosing party, or which shall have become publicly disclosed (other
than by breach of the receiving party's obligations hereunder).
(iv) To any investor pursuant to any appropriate request for
information, so long as such investor shall have executed a confidentiality
agreement in customary form.
(e) Covenants. Until such time that the Series B Preferred Stock has
been converted, redeemed or otherwise repaid in full, the Company shall not,
without the prior written consent of EIS, (1) change its business or any
material line of business in any material respect, (2) create or cause to be
issued any shares of any class or series of preferred stock that shall be
senior, in right to receive dividends, payments upon liquidation or otherwise,
to the Series B Preferred Stock, (3) incur any indebtedness or obligation other
than working capital and/or equipment financings, that shall be customary for
companies with similar financial profiles to the Company, (4) enter into any
material transaction with any affiliate or any director, officer or employee of
the Company or any such affiliate other than on such terms that are no less
favorable to the Company than would be entered into with an unaffiliated third
party, or (5) encumber the shares of Newco Common Stock owned by the Company and
transferable to EIS upon exercise by EIS of its right to exchange the Series A
Preferred Stock for shares of Newco Common Stock.
(f) Further Assurances. From and after the date hereof, each of the
parties hereto agree to do or cause to be done such further acts and things and
deliver or cause to be delivered to each other such additional assignments,
agreements, powers and instruments, as each may reasonably require or deem
advisable to carry into effect the purposes of the Transaction Documents.
SECTION 5. Company Board of Directors. For so long as (i) EIS and/or
its affiliates or subsidiaries collectively own securities that represent
ownership of at least 10% of the Common Stock (or securities convertible,
exchangeable or exercisable for or into Celtrix Common Stock) on a fully diluted
basis, assuming the exercise, conversion or exchange by EIS and its affiliates
of Preferred Stock to Common Stock, EIS shall be entitled to appoint one
director ("EIS Director") to the Company's board of directors who shall be
reasonably acceptable to the Company; provided, however, that the Company
reserves the right to exclude such EIS Director from any material or meeting or
portion thereof if the other Board members believe in good faith that such
exclusion is reasonably necessary to protect confidential proprietary
information, competitive or similar reasons.
SECTION 6. Survival and Indemnification. (a) Survival Period. The
representations and warranties of the Company and EIS contained herein shall
survive for a period of 24 months from and after the date hereof.
(b) Indemnification. In addition to all rights and remedies available
to the parties hereto at law or in equity, the parties (each, in such capacity,
an "Indemnifying Party"; together, "Indemnifying Parties") shall indemnify each
other as corporate entities (EIS and the Company), its stockholders,
12
<PAGE>
officers, directors and assigns, their affiliates, and its affiliates'
stockholders, officers, directors, employees, agents, representatives,
successors and assigns (collectively, the "Indemnified Person"), and save and
hold each Indemnified Person harmless from and against and pay on behalf of or
reimburse each such Indemnified Person, as and when incurred, for any and all
loss, liability, demand, claim, action, cause of action, cost, damage,
deficiency, tax, penalty, fine or expense, whether or not arising out of any
claims by or on behalf of such Indemnified Person or any third party, including
interest, penalties, reasonable attorneys' fees and expenses and all amounts
paid in investigation, defense or settlement of any of the foregoing
(collectively, "Losses"), that any such Indemnified Person may suffer, sustain
incur or become subject to, as a result of, in connection with, relating or
incidental to or by virtue of:
(i) any misrepresentation or breach of warranty on the part of
the Indemnifying Party in the case of the Company under Section 2 of this
Agreement or in the case of EIS under Section 3 of this Agreement or any of the
other Transaction Documents; or
(ii) any nonfulfillment, default or breach of any covenant or
agreement on the part of the Indemnifying Party under Section 4 of this
Agreement or any of the other Transaction Documents.
(c) Maximum Recovery. Notwithstanding anything in this Agreement to
the contrary, in no event shall the Indemnifying Parties be liable in the case
of the Company for indemnification under this Section 7 in an amount in excess
of, in the case of the Company, $4.8 million or, in the case of EIS, $100,000.
No Indemnified Person shall assert any such claim unless Losses in respect
thereof incurred by any Indemnified Person, when aggregated with all previous
Losses hereunder, equal or exceed U.S.$50,000, but at such time that an
Indemnified Person is entitled to assert a claim, such claim shall include all
Losses covered by this Section 7.
(d) Exception. Notwithstanding the foregoing, upon judicial
determination that is final and no longer appealable, that the act or omission
giving rise to the indemnification set forth above resulted primarily out of or
was based primarily upon the Indemnified Person's negligence (unless such
Indemnified Person's negligence was based upon the Indemnified Person's reliance
in good faith upon any of the representations, warranties, covenants or promises
made by the Indemnifying Party herein) the Indemnifying Party shall not be
responsible for any Losses sought to be indemnified in connection therewith, and
the Indemnifying Party shall be entitled to recover from the Indemnified Person
all amounts previously paid in full or partial satisfaction of such indemnity,
together with all costs and expenses (including reasonable attorneys fees) of
the Indemnifying Party reasonably incurred in connection with the Indemnified
Person's claim for indemnity, together with interest at the rate per annum
publicly announced by Morgan Guaranty Trust Company as its prime rate from the
time of payment of such amounts to the Indemnified Person until repayment to the
Indemnifying Party.
(e) Investigation. All indemnification rights hereunder shall survive
the execution and delivery of this Agreement and the consummation of the
transactions contemplated hereby to the extent provided in Section 7(g) below,
irrespective of any investigation, inquiry or examination made for or on behalf
of, or any knowledge of the
13
<PAGE>
Indemnified Person or the acceptance of any certificate or opinion.
(f) Contribution. If the indemnity provided for in this Section 7
shall be, in whole or in part, unavailable to any Indemnified Person, due to
Section 7(b) being declared unenforceable by a court of competent jurisdiction
based upon reasons of public policy, so that Section 7(b) shall be insufficient
to hold each such Indemnified Person harmless from Losses which would otherwise
be indemnified hereunder, then the Indemnifying Party and the Indemnified Person
shall each contribute to the amount paid or payable for such Loss in such
proportion as is appropriate to reflect not only the relative benefits received
by the Indemnifying Party on the one hand and the Indemnified Person on the
other, but also the relative fault of the Indemnifying Party and be in addition
to any liability that the Indemnifying Party may otherwise have. The indemnity,
contribution and expense reimbursement obligations that the Indemnifying Party
has under this Section 7 shall survive the expiration of the Transaction
Documents. The parties hereto further agree that the indemnification and
reimbursement commitments set forth in this Agreement shall apply whether or not
the Indemnified Person is a formal party to any such lawsuit, claims or other
proceedings.
(g) Limitation. No claim shall be brought by an Indemnified Person in
respect of any misrepresentation or breach of warranty under this Agreement
after 24 months from the date hereof; and any claim for nonfulfillment, default
or breach of any covenant shall be brought within one year of the date of that
such Indemnified Person became aware or should have become aware of the
nonfulfillment, default or breach. Except as set forth in the previous sentence
and in Section 7(c) above, this Section 7 is not intended to limit the rights or
remedies otherwise available to any party hereto with respect to this Agreement
or the Transaction Documents.
SECTION 7. Notices. All notices, demands and requests of any kind to
be delivered to any party in connection with this Agreement shall be in writing
and shall be deemed to have been duly given if personally or hand delivered or
if sent by an internationally-recognized overnight delivery, by facsimile or by
registered or certified airmail, return receipt requested and postage prepaid,
addressed as follows:
(i) if to the Company, to:
Celtrix Pharmaceuticals Inc.
2033 Gateway Place
Suite 600
San Jose, CA 95110
Attn: Andreas Sommer
Facsimile: (408) 573-6228
with a copy to:
Venture Law Group
2800 Sand Hill Road
14
<PAGE>
Menlo Park, CA 94025
Attention: Ned Ruffin
Facsimile: (650) 233-8386
(ii) if to EIS, to:
Elan International Services, Ltd.
Flatts, Smiths Parish
Bermuda, FL 04
Attention: Director
Facsimile: (441) 292-2224
with a copy to:
Brock Silverstein LLC
153 East 53rd Street , 56th Floor
New York, New York 10022
Attention: David Robbins, Esq.
Facsimile: (212) 371-2000
or to such other address as the party to whom notice is to be given may have
furnished to the other party hereto in writing in accordance with provisions of
this Section 8. Any such notice or communication shall be deemed to have been
effectively given (i) in the case of personal or hand delivery, on the date of
such delivery, (ii) in the case of an internationally-recognized overnight
delivery service, on the second business day after the date when sent, (iii) if
sent by facsimile, upon electronic confirmation of successful transmission and
(iv) in the case of mailing, on the fifth business day following that day on
which the piece of mail containing such communication is posted. Notice
hereunder may be given on behalf of the parties by their respective attorneys.
SECTION 8. Entire Agreement. This Agreement and the other Transaction
Documents contain the entire understanding of the parties with respect to the
subject matter hereof and thereof and supersede all prior agreements and
understandings among the parties with respect thereto.
SECTION 9. Amendments. This Agreement may not be modified or amended,
or any of the provisions hereof waived, except by written agreement of the
Company and EIS.
SECTION 10. Counterparts and Facsimile. The Transaction Documents may
be executed in any number of counterparts, and each such counterpart hereof
shall be deemed to be an original instrument, but all such counterparts together
shall constitute one agreement. Each of the Transaction Documents may be signed
and delivered to the other party by facsimile transmission; such transmission
shall be deemed a valid signature.
SECTION 11. Headings. The section and paragraph headings contained in
this Agreement are for reference purposes only and shall not affect in any way
the meaning or
15
<PAGE>
interpretation of the Agreement.
SECTION 12. Governing Law. This Agreement shall be governed by and
construed in accordance with the substantive (as opposed to procedural) laws of
the State of New York, without giving effect to principles thereof relating to
conflicts of laws
SECTION 13. Disputes. Any dispute under the Transaction Documents that
is not settled by mutual consent shall be finally adjudicated by any federal or
state court sitting in the County, City and State of New York; and each party
consents to the exclusive jurisdiction of such courts (and any appellate court
therefrom) over any such dispute.
SECTION 14. Expenses. Each of the parties shall be responsible for its
own costs and expenses incurred in connection with the transactions contemplated
hereby and by the other Transaction Documents.
SECTION 15. Schedules, etc. All statements contained in any exhibit or
schedule delivered by or on behalf of the parties hereto, or in connection with
the transactions contemplated hereby, are an integral part of this Agreement and
shall be deemed representations and warranties hereunder.
SECTION 16. Assignments and Transfers. This Agreement and all of the
provisions hereof shall be binding upon and inure to the benefit of the parties
hereto and their respective successors and permitted assigns. This Agreement,
the shares of Series A Preferred Stock and Series B Preferred Stock being
purchased hereunder by EIS, and the shares of Common Stock underlying the Series
A Preferred Stock and the Series B Preferred Stock may be transferred by EIS to
its affiliates and subsidiaries or, in the case of such securities and with the
prior written consent of the Company, which consent will not be unreasonably
withheld, any other third party; provided, that EIS shall remain liable for its
obligations hereunder after any such assignment. Other than as set forth above,
no party shall transfer or assign this Agreement or any interest therein,
without the prior written consent of the other party.
SECTION 18. Severability. In case any provision of this Agreement
shall be invalid, illegal or unenforceable, the validity, legality and
enforceability of the remaining provisions shall not be in any way affected or
impaired thereby.
16
<PAGE>
IN WITNESS WHEREOF, each of the undersigned has duly executed this
Agreement as of the date first written above.
CELTRIX PHARMACEUTICALS INC.
By:
-------------------------------------
Name: Andreas Sommer
Title: President and Chief Executive Officer
ELAN INTERNATIONAL SERVICES, LTD.
By:
-------------------------------------
Name: Kevin Insley
Title: President
17
